OBJECTIVES: To describe and compare integrase strand transfer inhibitor (INSTI) adverse drug reactions (ADRs) for raltegravir, elvitegravir-cobicistat, and dolutegravir. DESIGN: Population-based, retrospective cohort. METHODS: Antiretroviral-experienced and naive persons at least 19 years old were included if they received their first prescription for raltegravir, elvitegravir-cobicistat, or dolutegravir in British Columbia, Canada, in 2012-2014, and were followed for 2 years until 31 December 2016. The primary outcome was an ADR resulting in INSTI discontinuation. ADR rates and 95% confidence intervals (95% CIs) were calculated by Poisson method. Cox proportional-hazards regression estimated the hazard ratio for ADR-related INSTI discontinuation, adjusted for confounders. ADR symptoms were compared across INSTIs. RESULTS: There were 1344 persons contributing 1464 person-INSTI exposures. The cohort was predominantly male (79%) and antiretroviral therapy-experienced (85%). ADR events and unadjusted ADR rates (95% CI) per 100 person-years were raltegravir 24 of 551 (4.4%), 2.91 (1.95, 4.35); elvitegravir-cobicistat 38 of 394 (9.6%), 5.94 (4.32, 8.16); and dolutegravir 27 of 519 (5.2%), 2.96 (2.03, 4.31). The ADR rate for elvitegravir-cobicistat was double that of dolutegravir (adjusted hazard ratio 2.24, 95% CI 1.13, 4.44), but not significantly different for either dolutegravir or elvitegravir versus raltegravir. Elvitegravir-cobicistat-treated persons had a significantly higher proportion of gastrointestinal and general (fatigue, malaise) ADRs. Neuropsychiatric ADRs were more frequent with dolutegravir, but not significantly different between INSTIs. Among those switching between INSTIs, there was no apparent relationship between experiencing an ADR to one INSTI and subsequent intolerance to another. CONCLUSIONS: This study affirms INSTIs are well tolerated during routine clinical use. Consideration of differences in side effect profiles can inform antiretroviral therapy individualization.
OBJECTIVES: To describe and compare integrase strand transfer inhibitor (INSTI) adverse drug reactions (ADRs) for raltegravir, elvitegravir-cobicistat, and dolutegravir. DESIGN: Population-based, retrospective cohort. METHODS: Antiretroviral-experienced and naive persons at least 19 years old were included if they received their first prescription for raltegravir, elvitegravir-cobicistat, or dolutegravir in British Columbia, Canada, in 2012-2014, and were followed for 2 years until 31 December 2016. The primary outcome was an ADR resulting in INSTI discontinuation. ADR rates and 95% confidence intervals (95% CIs) were calculated by Poisson method. Cox proportional-hazards regression estimated the hazard ratio for ADR-related INSTI discontinuation, adjusted for confounders. ADR symptoms were compared across INSTIs. RESULTS: There were 1344 persons contributing 1464 person-INSTI exposures. The cohort was predominantly male (79%) and antiretroviral therapy-experienced (85%). ADR events and unadjusted ADR rates (95% CI) per 100 person-years were raltegravir 24 of 551 (4.4%), 2.91 (1.95, 4.35); elvitegravir-cobicistat 38 of 394 (9.6%), 5.94 (4.32, 8.16); and dolutegravir 27 of 519 (5.2%), 2.96 (2.03, 4.31). The ADR rate for elvitegravir-cobicistat was double that of dolutegravir (adjusted hazard ratio 2.24, 95% CI 1.13, 4.44), but not significantly different for either dolutegravir or elvitegravir versus raltegravir. Elvitegravir-cobicistat-treated persons had a significantly higher proportion of gastrointestinal and general (fatigue, malaise) ADRs. Neuropsychiatric ADRs were more frequent with dolutegravir, but not significantly different between INSTIs. Among those switching between INSTIs, there was no apparent relationship between experiencing an ADR to one INSTI and subsequent intolerance to another. CONCLUSIONS: This study affirms INSTIs are well tolerated during routine clinical use. Consideration of differences in side effect profiles can inform antiretroviral therapy individualization.
Authors: Samuel F Freedman; Carrie Johnston; John J Faragon; Eugenia L Siegler; Tessa Del Carmen Journal: Eur Geriatr Med Date: 2018-12-06 Impact factor: 1.710
Authors: Ronald Kiguba; Norah Mwebaza; Ronald Ssenyonga; Helen Byomire Ndagije; Victoria Nambasa; Cordelia Katureebe; Kenneth Katumba; Phil Tregunno; Kendal Harrison; Charles Karamagi; Kathryn A Scott; Munir Pirmohamed Journal: BMJ Open Date: 2022-07-01 Impact factor: 3.006
Authors: Lucia Taramasso; Paolo Bonfanti; Elena Ricci; Giancarlo Orofino; Nicola Squillace; Barbara Menzaghi; Giuseppe Vittorio De Socio; Giordano Madeddu; Giovanni Francesco Pellicanò; Layla Pagnucco; Benedetto Maurizio Celesia; Leonardo Calza; Federico Conti; Canio Vito Martinelli; Laura Valsecchi; Antonio Cascio; Cesare Bolla; Paolo Maggi; Francesca Vichi; Chiara Dentone; Goffredo Angioni; Antonio Mastroianni; Katia Falasca; Giovanni Cenderello; Antonio Di Biagio Journal: Open Forum Infect Dis Date: 2020-05-26 Impact factor: 3.835
Authors: Kimia Kamelian; Katherine J Lepik; William Chau; Benita Yip; Wendy W Zhang; Viviane Dias Lima; Marjorie A Robbins; Conan Woods; Andrea Olmstead; Jeffrey B Joy; Rolando Barrios; P Richard Harrigan Journal: Open Forum Infect Dis Date: 2019-02-12 Impact factor: 3.835
Authors: Elżbieta Jabłonowska; Ewa Siwak; Monika Bociąga-Jasik; Jacek Gąsiorowski; Anna Kalinowska; Ewa Firląg Burkacka; Kamila Wójcik-Cichy; Anna Piątek; Iwona Cielniak; Andrzej Horban Journal: PLoS One Date: 2019-01-17 Impact factor: 3.240
Authors: Kissa W Mwamwitwa; Adam M Fimbo; Elias M Bukundi; Alex F Nkayamba; Deus Buma; Eva P Muro; Betty A Maganda; Danstan H Shewiyo; Morven C Shearer; Andrew D Smith; Eliangiringa A Kaale Journal: Sci Rep Date: 2022-09-27 Impact factor: 4.996
Authors: Kimberly K Scarsi; Joshua P Havens; Anthony T Podany; Sean N Avedissian; Courtney V Fletcher Journal: Drugs Date: 2020-11 Impact factor: 9.546
Authors: Julián Olalla; Javier Pérez-Stachowski; Begoña Tortajada; Alfonso Del Arco; Efrén Márquez; Javier De la Torre; Miriam Nieto; José María García de Lomas; José Luis Prada; Javier García-Alegría Journal: BMC Pharmacol Toxicol Date: 2018-10-10 Impact factor: 2.483
Authors: Andrea Giacomelli; Alice Ranzani; Letizia Oreni; Elena Gervasi; Angelica Lupo; Anna Lisa Ridolfo; Massimo Galli; Stefano Rusconi Journal: Drug Des Devel Ther Date: 2019-07-09 Impact factor: 4.162